Novo Nordisk ADR Surges 3% Following UK Approval of Wegovy Weight-Loss Drug

Novo Nordisk's American Depositary Receipts (ADR) gained 3% following UK approval of its Wegovy weight-loss medication. The approval marks regulatory clearance for the GLP-1 receptor agonist in the British market.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments